Category Archives : News

Home  >>  News

DKFZ: Natural Killer cells contain powerful toxin against tumors

On May 30, 2016, Posted by , In News, With No Comments

Scientists at the University Hospital and the DKFZ in Heidelberg have discovered that a protein from immune cells paralyzes the energy supply in tumor cells. The German Society of Pathology has awarded them with the Novartis Prize. The scientists have now published their findings in Nature Communications. This potentially new…

Universität Heidelberg Garners Four Approvals for Collaborative Research Centres

On May 27, 2016, Posted by , In News, With No Comments

DFG funds three newly approved research networks and one CRC extension with more than 46 million euros Heidelberg University succeeded in gaining support from the German Research Foundation (DFG) in the latest approval round, recieving funding for four research networks. The DFG granted funds to the new Transregional Collaborative Research…

Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing

On May 23, 2016, Posted by , In News, With No Comments

Aims to identify maladaptive brain circuits to find new approaches for treating psychiatric diseases Second Boehringer Ingelheim crowdsourcing project with BioMed X builds on success of previous project focused on epigenetic drivers of COPD New research team at the BioMed X Innovation Center will complement Boehringer Ingelheim’s broad research and…

EMBL: Making cells move towards the light

On May 20, 2016, Posted by , In News, With No Comments

Thanks to a new method developed by the Schultz lab at EMBL, scientists can use light to direct where cancer cells go An airplane leaving a lit-up runway is not the kind of image you’d expect to see on the cover of a scientific journal, but there it is on…

Ascendis Pharma A/S Reports First Quarter 2016 Financial Results

On May 19, 2016, Posted by , In News, With No Comments

Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three months ended March 31, 2016. “The execution of our TransCon Growth Hormone clinical development plan remains on track and we look…

VAXIMM Announces Data from Phase I Trial in Pancreatic Cancer with Oral T-cell Immunotherapy VXM01 to be Presented at ASCO 2016 Annual Meeting

On May 19, 2016, Posted by , In News, With No Comments

Basel (Switzerland) and Mannheim (Germany), May 19, 2016 – VAXIMM AG, a Swiss-German biotech company focused on developing oral T-cell immunotherapies, today announced that data with its lead product candidate VXM01 in pancreatic cancer will be presented at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO)…

Merck Increases Sales and Earnings in Q1 Following Sigma-Aldrich Acquisition

On May 19, 2016, Posted by , In News, With No Comments

Healthcare and Life Science drive Group organic sales growth (+4.7%) Sigma-Aldrich acquisition fuels sales (+20.5%) and EBITDA pre exceptionals (+27.0%) Integration of Sigma-Aldrich proceeding according to plan Net financial debt lowered by around € 600 million Merck confirms and specifies outlook for 2016 Darmstadt, Germany, May 19, 2016 – Merck,…

Phase III study of Roche’s Alecensa (alectinib) showed superior efficacy versus crizotinib in Japanese people with a specific type of lung cancer

On May 19, 2016, Posted by , In News, With No Comments

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Alecensa® , an oral anaplastic lymphoma kinase (ALK) inhibitor, reduced the risk of disease worsening or death (progression free survival, PFS) by 66 percent compared to crizotinib in Japanese people with advanced or recurrent, ALK-positive non-small cell lung cancer (NSCLC) (hazard…

FDA grants Roche’s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer

On May 19, 2016, Posted by , In News, With No Comments

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tecentriq® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-based chemotherapy, or whose disease has worsened within…

Affimed Reports Financial Results for First Quarter 2016

On May 18, 2016, Posted by , In News, With No Comments

Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported financial results for the quarter ended March 31, 2016. “IO combination therapies, like our lead drug AFM13 in combination with our partner Merck’s Keytruda, may offer a similarly high efficacy…